Nanoviricides reports that its two COVID-19 drug candidates have been “highly effective” against the virus in pre-clinical laboratory studies. The Shelton-based company is preparing a pre-IND (investigational new drug) application for the two treatments.
These include Its lead drug candidate, NV-CoV-2, and NV-CoV-2-R. The latter combines both NV-CoV-2 and remdesivir in a single drug.